GLOW – 70mg

GLOW is a defined three-component research blend combining GHK-Cu, BPC-157 and TB-500 in a single lyophilised preparation.

This 70mg format contains 50mg GHK-Cu, 10mg BPC-157 and 10mg TB-500, providing a fixed 5:1:1 composition by mass.

Each component has a distinct research profile.

GHK-Cu is a copper-binding tripeptide investigated extensively in fibroblast, collagen and extracellular-matrix research. BPC-157 is a 15-amino-acid peptide studied in experimental models involving fibroblast migration, cellular adhesion and connective-tissue biology. TB-500 is associated with the actin-binding region of thymosin beta-4 and is investigated in research involving cytoskeletal organisation and cell movement.

Combining these materials into one defined preparation therefore creates a research format spanning collagen and matrix biology, fibroblast behaviour, cellular migration and structural processes associated with tissue remodelling.

The published evidence for these biological areas comes principally from studies of the individual components rather than controlled research demonstrating equivalent or synergistic effects from the complete GLOW blend itself.

Pronoia supplies GLOW in a 70mg multi-component research format with batch traceability and supporting documentation available for the supplied material.

Product: GLOW

GHK-Cu content: 50mg

BPC-157 content: 10mg

TB-500 content: 10mg

Total content: 70mg

Blend ratio: 5:1:1 by mass

Material class: Multi-peptide research blend

Research focus: Fibroblast behaviour, collagen and extracellular-matrix biology, cell migration and tissue-remodelling research

Form: Lyophilised multi-component research preparation

Pronoia minimum purity standard: ≥99%

Batch traceability: Maintained

SKU: PB-GLOW-70

Pronoia maintains a structured quality, testing and traceability process for GLOW, with supporting documentation retained for the supplied research material.

• Batch-tested research material
• Pronoia minimum accepted purity standard of ≥99%
• Defined 50mg / 10mg / 10mg blend composition
• Full batch traceability
• Batch-separated and labelled inventory
• Physical inventory routinely reconciled with digital stock records
• Temperature-controlled cold storage
• Certificate of Analysis (COA) and Safety Data Sheet (SDS) documentation available

Because GLOW is a multi-component preparation, analytical reporting may differ from that used for a single isolated peptide.

The applicable Certificate of Analysis should therefore be treated as the authoritative reference for the identity, composition, purity and analytical results reported for an individual batch.

GLOW combines three distinct research materials whose published biological findings should be considered individually before considering the rationale for studying them within the same preparation.

There is currently substantially more published evidence for GHK-Cu, BPC-157 and TB-500 or thymosin-beta-4-related sequences individually than for the exact three-component GLOW formulation.

GHK-Cu — collagen and extracellular-matrix biology

GHK-Cu is a copper-binding tripeptide studied extensively in fibroblasts and experimental tissue-remodelling models.

Published research has reported:

• Increased collagen synthesis in cultured fibroblasts
• Increased extracellular-matrix-associated glycosaminoglycan production
• Increased type I and type III collagen expression in experimental wound models
• Changes in MMP-2, TIMP-1 and TIMP-2 associated with extracellular-matrix turnover and remodelling

These findings make the GHK-Cu component particularly relevant to research examining how connective-tissue matrix is produced, reorganised and remodelled.

BPC-157 — fibroblast behaviour and cell migration

BPC-157 has been investigated in tendon-derived fibroblast models examining cellular migration, spreading, survival and adhesion-related signalling.

Under specific experimental conditions, researchers reported:

• Increased migration of tendon-derived fibroblasts
• Increased fibroblast spreading
• Increased cell survival during experimentally induced oxidative stress
• Increased F-actin formation
• Increased activation of FAK and paxillin signalling associated with cellular adhesion and movement

These findings make BPC-157 relevant to experimental systems examining fibroblast behaviour, cellular movement and connective-tissue-response biology.

TB-500 — actin-associated and structural cell biology

Published analytical research on material described as TB-500 identified the N-terminally acetylated 17–23 fragment of thymosin beta-4, represented by the sequence Ac-LKKTETQ.

This sequence corresponds to a region associated with thymosin-beta-4 actin-binding biology. Actin is a major component of the cytoskeleton — the internal structural framework that enables cells to maintain shape, reorganise and move.

TB-500-related research therefore sits within experimental areas involving:

• Actin-associated cellular organisation
• Cell migration and motility
• Cytoskeletal dynamics
• Fibroblast and wound-model research

The TB-500 evidence requires particular care. Much of the broader biological literature frequently associated with TB-500 derives from full-length thymosin beta-4 or related sequences rather than the acetylated fragment itself.

More recent experimental work examining TB-500 and its metabolites has also suggested that biological activity observed in wound-healing assays may differ between the parent fragment and its metabolites.

Why study the components together?

The scientific rationale for a GLOW-type preparation comes from the different but overlapping research territories represented by its components:

• GHK-Cu contributes copper-peptide, collagen and extracellular-matrix research
• BPC-157 contributes fibroblast migration, adhesion and connective-tissue-response research
• TB-500 contributes actin-associated, cytoskeletal and cell-migration research

A fixed preparation allows these compounds to be present within the same experimental system at a defined composition, making the blend relevant to studies examining multiple cellular and tissue-remodelling pathways in parallel.

This should not be interpreted as evidence that the components act synergistically or that findings reported for each component individually have been demonstrated for the GLOW combination.

The available evidence remains primarily laboratory and preclinical. It does not establish clinical efficacy, safety or suitability for human or veterinary use.

GLOW is supplied in lyophilised form and should be stored according to the conditions specified by Pronoia and the applicable batch documentation.

Pronoia stock is maintained in temperature-controlled cold storage and organised by identifiable batch prior to dispatch.

The material should be protected from unnecessary exposure to heat, moisture and light and handled using appropriate laboratory procedures.

Because GLOW is a multi-component preparation containing GHK-Cu, some variation in colour or physical appearance may occur between supplied batches. Batch documentation and analytical results should be used when assessing product specification rather than appearance alone.

Where batch-specific storage or handling information is supplied, that information should take precedence.

GLOW is dispatched from Pronoia’s UK stock using tracked delivery.

Current availability and dispatch information are shown directly on the product page, with tracking supplied following dispatch.

Orders are prepared through Pronoia’s established research-product fulfilment process, with applicable delivery conditions remaining subject to Pronoia’s current delivery terms.

GLOW supplied by Pronoia Bio is intended for laboratory research and experimental use only.

It is not supplied for human or veterinary use and should not be treated as a medicine or consumer healthcare product.

Pronoia does not provide dosage, treatment or administration guidance for this research material.